Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Tessellate Bio logo — Redefining Synthetic Lethality beyond HRD

Tessellate Bio

Redefining Synthetic Lethality beyond HRD

Founded 2020 The Netherlands The Netherlands 28 employees Seed Total: $8.00M Biotechnology

General Information

Company Name Tessellate Bio
Founded Year 2020
Location The Netherlands The Netherlands
Employees 28
Industries Biotechnology
Funding Stage Seed
Business Model B2B, Platform
Revenue Model Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Tessellate Bio. To contact Tessellate Bio, visit tessellatebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Tessellate Bio compare?

A PDF of Tessellate Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Tessellate Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Tessellate Bio

Tessellate Bio, a biotechnology startup founded in 2020, is at the forefront of precision oncology. The company, with its slogan "Redefining Synthetic Lethality beyond HRD", is pioneering the development of novel cancer treatments by targeting previously unexplored pathways beyond HRD.

Operating out of its headquarters in The Netherlands and research labs in the Stevenage Bioscience Catalyst in the UK, the company is focused on turning cancer patients into survivors. Tessellate Bio stands out in the biotech sector by being at a preclinical stage yet attracting significant investments.

In its latest financing effort, the company secured a substantial €8.00M Seed Round investment as of October 17, 2023. This funding was led by prominent life science investors, BioGeneration Ventures and Forbion. The backing from these seasoned investors underscores confidence in Tessellate Bio's innovative approach and potential to disrupt the oncology field.

Business keywords: Synthetic Lethality, Precision Oncology, Preclinical Stage Biotechnology, Drug Discovery, Novel Medicine Development, Cancer Treatment, Oncology Research, Advanced Drug Development, Tumor Targeting Therapies, Unmet Medical Needs, Life Science Investment, Drug Targeting Pathways

Services & Products

Development of Precision Oncology Medicines
Biomarker-Incorporated Drug Discovery
Pipeline Building for Novel Cancer Treatments

Target Customers

Cancer Patients Healthcare Providers Pharmaceutical Partners Research Institutions

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round €8.00M 2
BioGeneration Ventures Forbion
BioGeneration Ventures, Forbion
17 Oct 2023

Tessellate Bio Alternatives & Competitors

View All Alternatives
Tessellate Bio vs
Tango Therapeutics
Tango Therapeutics United States

Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medic...

Post-IPO Equity
182 employees
Biotechnology, Health Care
Compare Tessellate Bio vs Tango Therapeutics
Tessellate Bio vs
Repare Therapeutics
Repare Therapeutics Canada

A leading precision oncology company focused on synthetic lethality

45 employees
Biotechnology, Pharmaceutical
Compare Tessellate Bio vs Repare Therapeutics
Tessellate Bio vs
Chordia Therapeutics Inc
Chordia Therapeutics Inc Japan

We are passionate to deliver first in class cancer drugs to patients from Japan.

IPO
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About Tessellate Bio

Redefining Synthetic Lethality beyond HRD
Tessellate Bio was founded in 2020.
Tessellate Bio is headquartered in The Netherlands.
Tessellate Bio operates in Biotechnology. Its work centres on Synthetic Lethality, Precision Oncology, Preclinical Stage Biotechnology and Drug Discovery. Its customers include Cancer Patients, Healthcare Providers and Pharmaceutical Partners.
Tessellate Bio has a B2B and Platform business model. Its revenue comes from Licensing and Performance Based.
Tessellate Bio has approximately 28 employees.
Tessellate Bio has completed 1 funding round, raising a total of $8.00M. The latest funding stage is Seed.
Tessellate Bio offers: Development of Precision Oncology Medicines, Biomarker-Incorporated Drug Discovery, Pipeline Building for Novel Cancer Treatments.
Top alternatives and competitors to Tessellate Bio include Tango Therapeutics, Repare Therapeutics, Chordia Therapeutics Inc, VRise Therapeutics, Inc., Lisata Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Tessellate Bio and Tango Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Tessellate Bio, https://bouncewatch.com/company/tessellate-bio, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout